Matthew A. Wanat

Matthew A. Wanat

Auto-generated profile, based on publicly available information

Matthew A. Wanat

University of Houston College of Pharmacy, TX, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2019 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
LSLuma Succar
Luma Succar
ESElisabeth M. Sulaica
Elisabeth M. Sulaica
KDKevin R. Donahue
Kevin R. Donahue
MWMatthew A. Wanat
Matthew A. Wanat

19 January 2015 in Clinical and Applied Thrombosis/Hemostasis
Verified
Journal Article
Closed access
NTNathaniel R. Thompson-Moore
Nathaniel R. Thompson-Moore
MWMatthew A. Wanat
Matthew A. Wanat
DPDavid R. Putney
David R. Putney
PLPhuong H. Nguyen Liebl
Phuong H. Nguyen Liebl
WCWayne L. Chandler
Wayne L. Chandler
JMJames E. Muntz
James E. Muntz
Background: The pharmacokinetic properties of enoxaparin may lead to supratherapeutic antifactor Xa (anti-Xa) levels and increased bleeding when standard treatment doses are used in patients with morbid obesity. Objective: To evaluate the dose of enoxaparin needed to achieve therapeutic anti-Xa levels in a prospective, masked observational cohort of heterogeneous inpatients with morbid obesity and to determine whether patients with morbid obesity treated with 1 mg/kg of enoxaparin are at increased risk of supratherapeutic levels and bleeding events compared to patients receiving lower doses. Methods: Hospitalized patients with a body mass index ≥40 kg/m2 or actual body weight ≥140 kg and prescribed treatment doses of enoxaparin >60 mg per day were enrolled and consented to phlebotomy for determination of anti-Xa levels. Results: Forty-one patients were included for data analysis. The dose of enoxaparin that resulted in therapeutic and supratherapeutic anti-Xa levels at steady state was 0.83 mg/kg and 0.98 mg/kg (−0.11; 95% confidence interval [CI] −0.20 to −0.01, P = .02), respectively. Enoxaparin dose as mg/kg of actual body weight was an independent predictor of having a supratherapeutic anti-Xa level. Patients with doses <0.95 mg/kg versus ≥0.95 mg/kg were less likely to have supratherapeutic levels (odds ratio 0.21 [95% CI 0.05-0.84], P = .02) and had similar rates of subtherapeutic levels. Doses <0.95 mg/kg and ≥0.95 mg/kg resulted in similar bleeding rates of 17.9% and 22.2% ( P = .71), respectively. Conclusion: Patients with morbid obesity required less than the recommended 1 mg/kg enoxaparin dose to achieve therapeutic peak anti-Xa levels; therefore, initiation with lower dosages is prudent and anti-Xa monitoring should guide dosage adjustments.

1 April 2014 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Closed access
MWMatthew Wanat
Matthew Wanat
KFKalliopi Fitousis
Kalliopi Fitousis
FBFariedeh Boston
Fariedeh Boston
FMFaisal Masud
Faisal Masud
Many cardiovascular surgeries are fast-tracked to extubation and require short-term sedation. Dexmedetomidine and propofol have very different mechanisms of action and pharmacokinetic profiles that make them attractive sedative agents in this patient population. Recently, there has been increased use of dexmedetomidine in the intensive care unit (ICU), but few studies exist or have been published directly comparing both agents in this setting. We conducted a retrospective cohort study with patients admitted to the ICU after cardiovascular surgery from January through June 2011. Adult patients who underwent coronary artery bypass and/or cardiac valve surgery received either dexmedetomidine or propofol continuous infusion for short-term sedation after cardiovascular surgery. The primary end point was time (hours) on mechanical ventilation after surgery. Secondary end points included ICU length of stay (LOS), hospital LOS, incidence of delirium, and requirement of a second sedative agent. A total of 352 patients met study inclusion criteria, with 33 enrolled in the dexmedetomidine group and 319 in the propofol group. Time on mechanical ventilation was shorter in the dexmedetomidine group (7.4 hours vs. 12.9 hours, P = .042). No difference was seen in ICU or hospital LOS. The need for a second sedative agent to achieve optimal sedation (24% vs. 27%, P = .737) and incidence of delirium (9% vs. 7.5%, P = .747) were similar between both groups. Sedation with dexmedetomidine resulted in a significant reduction in time on mechanical ventilation. However, no difference was seen in ICU or hospital LOS, incidence of delirium, or mortality.

1 November 2019 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
TVTyler J. Varisco
Tyler J. Varisco
Marc L FlemingMarc L Fleming
Marc L Fleming
SBShweta S. Bapat
Shweta S. Bapat
MWMatthew A. Wanat
Matthew A. Wanat
JTJames Douglas Thornton
James Douglas Thornton

29 May 2019 in Expert Review of Cardiovascular Therapy
Verified
Journal Article
Closed access
AMAnjana Mohan
Anjana Mohan
MWMatthew A. Wanat
Matthew A. Wanat
SASusan Abughosh
Susan Abughosh
Introduction: This article aims to compare medication adherence and persistence between warfarin and direct oral anticoagulants (DOACs) and identify reported adherence barriers. As with other chronic illness, medication nonadherence continues to be a problem and appropriate adherence to long-term anticoagulation therapy is needed to improve patient health outcomes and to reduce health expenditure associated with hospitalizations and emergency visits. Areas covered: Warfarin and DOACs such as apixaban, rivaroxaban, edoxaban, and dabigatran have demonstrated effectiveness in the management of atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE). Adherence and long-term persistence to oral anticoagulants is highly associated with reduced adverse events. A systematic literature search from 2013-2018 examined the primary outcome of adherence and persistence. Expert commentary: Currently, warfarin is less preferred over DOACs due to associated complications like narrow therapeutic window, inconvenience and increased risk of adverse events. At the same time, the lack of monitoring with DOACs in combination with cost issues may negatively impact medication adherence. Examining adherence barriers identified in the literature is the first step to designing effective interventions aimed at enhancing adherence in this high-risk population.

1 November 2013 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
MWMatthew A. Wanat
Matthew A. Wanat
KGKevin W Garey
Kevin W Garey
With the increase of new pharmacy colleges and schools throughout the country, the number of open clinical academic pharmacy positions continues to grow. Considering the abundance of clinical faculty positions available nationwide and the increased likelihood of current pharmacy residents transitioning from residency directly into academia, pharmacy residents must be prepared to succeed in the role of new clinical faculty member. However, no blueprint or recommendations have yet been provided to facilitate this transition. The purpose of this review article is to evaluate the literature regarding transitioning pharmacy students and/or residents into faculty roles. The literature reviewed represents nursing, medical, graduate school, and engineering disciplines because no literature on this topic was available from the pharmacy profession. Based on the recommendations provided in the literature and on the authors’ experience at their college, they created a blueprint consisting of 7 components to help resi...